MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

Q2 2025 Earnings Call Transcript August 12, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.32. Operator: Good morning, ladies and gentlemen, and ...

Altimmune ( ($ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc. is ...

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise ...

Altimmune (NASDAQ:ALT) shares surge 8% post-promising Q2 results, driven by pemvidutide's success in metabolic and liver conditions. Read more here.

UC Davis Health researchers have discovered that a natural molecule made by gut bacteria can reverse liver damage and repair ...

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

Altimmune, Inc. ( NASDAQ: ALT) Q2 2025 Earnings Call August 12, 2025 8:30 AM ET Gregory L. Weaver - Chief Financial Officer Scott Harris - Corporate Participant Vipin K. Garg - President, CEO & ...

Liver cancer is the sixth most common cancer in the world, with around 870,000 cases in 2022. That’s projected to increase to 1.52 million cases in 2050, the new report found, if no changes are ...

At least 60% of liver cancers globally could be prevented with control of certain risk factors, including viral hepatitis, alcohol use, and metabolic dysfunction-associated steatotic liver disease ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are ...

Prisma Health's Transplant Center in Greenville, SC, now performs liver transplants, expanding access for patients in the region.